Andrew Baum, Pfizer's chief strategy and innovation officer, talked Thursday about the pharmaceutical company's drug ...

In his first public comments, Pfizer’s new innovation chief — once a Wall Street analyst skeptical of the company — said he was confident in the company’s obesity plans and shed light on ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

In vaccines, Pfizer plans to start a Phase 3 study for PCV ... study is critical for Pfizer’s entry into the lucrative obesity market. It is still in progress, with data expected in Q1-CY25.

Pfizer and partner ... loss of 25%. NVO plans to file regulatory applications seeking approval for CagriSema in the first quarter of 2026. Roche Buys Rights to Obesity Drug from Zealand Pharma ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

There’s no question, however, that the decision to abandon the twice-daily version introduces a significant delay to Pfizer’s plans to enter the obesity market, which has been transformed in ...

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The restrictions began because the FDA declared a shortage of tirzepatide, often ...